Purpose Psychotropic and somatic medications are both used in treating severe mental
disorders (SMDs). Realistic estimates of the prevalence of use across medication categories …

Objective To investigate the clustering of physical health multimorbidity in people with
severe mental illness (SMI) compared to matched comparators. Design A cohort-nested …

Patients with schizophrenia have substantial comorbidity contributing to reduced life
expectancy of 10–20 years. Identifying which comorbidities might be modifiable could …

Background Patients with schizophrenia have substantial comorbidity that contributes to
reduced life expectancy of 10 to 20 years. Identifying modifiable comorbidities could improve …

Schizophrenia is a severe mental illness characterized by psychotic symptoms (especially
auditory hallucinations, paranoia, other delusions), negative symptoms (social withdrawal …

Background People with schizophrenia have shortened lives. This excess mortality seems to
be related to physical health conditions that may be amenable to better primary and …

The objectives of this study were to identify the prevalence of comorbidities of mental and
behavioral disorders and to identify the association rules related to comorbidities as a way to …

Introduction The aim of this study is to analyse different ways of participation during the
development of a clinical guideline to improve the early detection of psychosis and to deploy …

Background: Comorbid somatic diseases increase the death risk and affect the condition,
treatment, and prognosis of older psychiatric patients. We investigated the comorbidity and …

In addition to increasing the risk of premature mortality, accumulating evidence indicates that
various CPIs affect schizophrenia treatment outcomes. Thus, researchers and healthcare …